Auflistung nach Autor "Eigentler, Thomas"

443 paediatric cases of malignant melanoma registered with the German Central Malignant Melanoma Registry between 1983 and 2011

Garbe, Claus; Leiter-Stöppke, Ulrike; Bauer, Jürgen; Eigentler, Thomas (2015)

A Case of Choroidal Melanoma Metastatic to the Breast

Ţǎran-Munteanu, Laura Cǎtǎlina Veturia; Hartkopf, Andreas; Eigentler, Thomas; Ţăran, Florin-Andrei; Brucker, Sara; Vogel, Ulrich Felix (2016)

A Machine learning model trained on dual-energy CT radiomics significantly improves immunotherapy response prediction for patients with stage IV melanoma

Brendlin, Andreas Stefan; Peisen, Felix; Afat, Saif; Amaral, Teresa; Nikolaou, Konstantin; Al Mansour, Haidara; Eigentler, Thomas; Othman, Ahmed (2021)

A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients

Weide, Benjamin Matthias; Eigentler, Thomas; Garbe, Claus (2019)

Absolute and relative differential blood count predicts survival of AJCC stage I-II melanoma patients scheduled for sentinel lymph node biopsy

Wagner, Nikolaus B.; Luttermann, Felix; Gassenmaier, Maximilian; Forschner, Andrea Lydia; Leiter-Stöppke, Ulrike; Garbe, Claus; Eigentler, Thomas (2020)

Acral lentiginous melanoma: a skin cancer with unfavourable prognostic features. A study of the German central malignant melanoma registry (CMMR) in 2050 patients

Teramoto, Yukiko; Keim, Ulrike; Leiter-Stöppke, Ulrike; Eigentler, Thomas; Garbe, Claus (2018)

Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial

Eigentler, Thomas; Garbe, Claus (2022)

Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial

Eigentler, Thomas; Garbe, Claus (2020)

Adjuvant therapy of Nivolumab combined with Ipilimumab versus Nivolumab alone in patients with resected stage IIIB-D or stage IV melanoma (CheckMate 915)

Eigentler, Thomas (2023)

Adjuvant treatment with pegylated interferon alpha-2a versus low-dose interferon alpha-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial(aEuro)

Eigentler, Thomas; Garbe, Claus (2016)

Age as key factor for pattern, timing, and extent of distant metastasis in patients with cutaneous melanoma: A study of the German Central Malignant Melanoma Registry

Gassenmaier, Maximilian; Keim, Ulrike; Leiter-Stöppke, Ulrike; Eigentler, Thomas; Röcken, Martin; Garbe, Claus (2019)

Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry

Amaral, Teresa; Flatz, Lukas; Thomas, Ioannis; Garbe, Claus; Eigentler, Thomas; Martus, Peter; Serna Higuita, Lina María; Forschner, Andrea Lydia; Leiter-Stöppke, Ulrike; Seeber, Tonia Olivia (2021)

Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

Eigentler, Thomas (2020)

Baseline clinical and imaging predictors of treatment response and overall survival of patients with metastatic melanoma undergoing immunotherapy

Gatidis, Sergios; Schraag, Amadeus Dominik; Klumpp, Bernhard; Afat, Saif; Nikolaou, Konstantin; Eigentler, Thomas; Othman, Ahmed (2019)

Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab

Martens, Alexander; Wistuba-Hamprecht, Kilian; Eigentler, Thomas; Martus, Peter; Pawelec, Graham; Garbe, Claus; Weide, Benjamin Matthias (2016)

BRAF-V600 Mutations Have No Prognostic Impact in Stage IV Melanoma Patients Treated with Monochemotherapy

Meckbach, Diana; Keim, Ulrike; Richter, Sabina; Eigentler, Thomas; Pflugfelder, Annette Dorothee; Garbe, Claus; Weide, Benjamin Matthias; Leiter-Stöppke, Ulrike; Bauer, Jürgen (2014)

Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours

Brenner, Ellen; Wieder, Thomas; Hilke, Franz Joachim; Simon, Nadine Maria; Schroeder, Christopher; Demidov, German; Fehrenbacher, Birgit; Schaller, Martin; Niessner, Heike; Sinnberg, Tobias; Zwirner, Stefan; Zender, Lars; Sonanini, Dominik; Eichner, Martin; Biskup, Saskia; Quintanilla-Martinez, Leticia; Kneilling, Manfred; Schörg, Barbara F.; Forschner, Andrea Lydia; Eigentler, Thomas; Böhm, Katharina; Braumüller, Heidi; Dauch, Daniel Alexander; Bauer, Jürgen; Döcker, Dennis Miklas; Pichler, Bernd; Röcken, Martin (2020)

Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive in vivo F-18-FDG-PET

Schwenck, Johannes Walter; Fiz, Francesco; Sonanini, Dominik; Martella, Manuela; Gonzalez Menendez, Irene; Seith, Ferdinand Frederic; Quintanilla-Martinez, Leticia; Garbe, Claus; Pfannenberg, Christina; Kneilling, Manfred; Schörg, Barbara F.; Forschner, Andrea Lydia; Eigentler, Thomas; Weide, Benjamin Matthias; Röcken, Martin; La Fougère, Christian Jean; Pichler, Bernd (2020)

Case report: Combined CDK4/6 and MEK inhibition in refractory CDKN2A and NRAS mutant melanoma

Forschner, Andrea Lydia; Sinnberg, Tobias; Decker-Mroz, Gabriele; Schroeder, Christopher; Reinert, Christian Philipp; Gatidis, Sergios; Bitzer, Michael; Eigentler, Thomas; Garbe, Claus; Niessner, Heike; Röcken, Martin; Roggia, Cristiana; Armeanu-Ebinger, Sorin; Rieß, Olaf; Mattern, Sven; Nann, Dominik; Bonzheim, Irina (2021)

CHEK2*1100delC and Risk of Malignant Melanoma: Danish and German Studies and Meta-Analysis

Garbe, Claus; Röcken, Martin; Eigentler, Thomas (2012)

Auflistung nach Autor "Eigentler, Thomas"

Auflistung nach Autor "Eigentler, Thomas"

Stöbern

Gesamter Bestand

Mein Benutzerkonto

Hilfe & Infos